CompletedPhase 3NCT03656926

Efficacy + Safety of Liposome Cyclosporine A to Treat Bronchiolitis Obliterans Post Double Lung Transplant (BOSTON-2)

Studying Bronchiolitis obliterans

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Zambon SpA
Principal Investigator
Paola Castellani, MD
Zambon SpA, Chief Medical Officer and R&D
Intervention
Liposomal Cyclosporine A(drug)
Enrollment
169 enrolled
Eligibility
18 years · All sexes
Timeline
20192024

Study locations (30)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT03656926 on ClinicalTrials.gov

Other trials for Bronchiolitis obliterans

Additional recruiting or active studies for the same condition.

See all trials for Bronchiolitis obliterans

← Back to all trials